Roche acquires Verum Diagnostica for 11 million euros

5 December 2011

Swiss drugs and diagnostics major Roche (ROG: SIX) has signed an agreement under which it will acquire 100% of Verum Diagnostica GmbH, based in Munich, Germany. Verum Diagnostica is a leading company in platelet function testing, the fastest-growing field in the coagulation diagnostics market.

Under the terms of the deal, Roche will pay Verum Diagnostica shareholders a total cash consideration of 11 million euros ($14.8 million), and potentially a further 2 million euros contingent upon reaching certain performance-related mile stones. The transaction is subject to customary closing conditions and is expected to close in January 2012.

Supports plans to expand coagulation testing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK